$Drug Repositioning for Refractory Benign Tumors of the Central Nervous System$

Drug Repositioning for Refractory Benign Tumors of the Central Nervous System

Drug repositioning (DR) is the process of identifying novel therapeutic potentials for already-approved drugs and discovering new therapies for untreated diseases. DR can play an important role in optimizing the pre-clinical process of developing novel drugs by saving time and cost compared with the...

Full description

Bibliographic Details
Main Author:	Ryota Tamura
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	International Journal of Molecular Sciences
Subjects:	drug repositioning drug repurposing schwannoma meningioma pituitary neuroendocrine tumor neurofibromatosis type 2-related schwannomatosis
Online Access:	https://www.mdpi.com/1422-0067/24/16/12997

Similar Items

Plexiform schwannoma of the floor of the mouth: a case report
by: Mohammad Koochek Dezfuli, et al.
Published: (2017-03-01)

Drug Repositioning for Hand, Foot, and Mouth Disease
by: Ran Yan, et al.
Published: (2022-12-01)

18F-FDG PET/CT revealed sporadic schwannomatosis involving the lumbar spinal canal and both lower limbs: a case report
by: Xiaotian Li, et al.
Published: (2024-03-01)

Central nervous system manifestations of neurofibromatosis type 2: A case report
by: Zineb Izi, MD, et al.
Published: (2023-08-01)

Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs
by: Daniele Parisi, et al.
Published: (2020-01-01)

Changing Trends in Computational Drug Repositioning
by: Jaswanth K. Yella, et al.
Published: (2018-06-01)

Multiple schwannomas, including a plexiform variant, in a patient in the absence of neurofibromatosis I or II
by: Snehlata R Hingway
Published: (2015-01-01)

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
by: Sha Zhu, et al.
Published: (2022-01-01)

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
by: Katharine Yu, et al.
Published: (2023-06-01)

Drug Repositioning for Effective Prostate Cancer Treatment
by: Beste Turanli, et al.
Published: (2018-05-01)

Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization
by: Héctor Hernández-Parra, et al.
Published: (2022-09-01)

Machine Learning for the Detection and Segmentation of Benign Tumors of the Central Nervous System: A Systematic Review
by: Paul Windisch, et al.
Published: (2022-05-01)

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis
by: Ryota Tamura
Published: (2021-05-01)

Neurofibromatosis 2
by: Abhijit M Patil, et al.
Published: (2015-01-01)

Drug repositioning for esophageal squamous cell carcinoma
by: Adam N. Bennett, et al.
Published: (2022-09-01)

Spinal schwannomatosis of the cauda equina in the absence of neurofibromatosis
by: Dana Turliuc, et al.
Published: (2017-03-01)

Prospects for repurposing CNS drugs for cancer treatment
by: Mohamed Abdelaleem, et al.
Published: (2019-04-01)

Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov
by: Eric Wen Su, et al.
Published: (2017-03-01)

Integrative rare disease biomedical profile based network supporting drug repurposing or repositioning, a case study of glioblastoma
by: Erin McGowan, et al.
Published: (2023-09-01)

Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
by: Joana M. O. Santos, et al.
Published: (2021-10-01)

Computational drug repositioning based on side-effects mined from social media
by: Timothy Nugent, et al.
Published: (2016-02-01)

Segmental schwannomatosis: characteristics in 12 patients
by: Abdulqader Alaidarous, et al.
Published: (2019-08-01)

Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study
by: Akram Sanagoo, et al.
Published: (2019-06-01)

Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma
by: Michele Persico, et al.
Published: (2022-01-01)

An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA)
by: Qiu Ying Lau, et al.
Published: (2015-10-01)

Elucidation of bioinformatic-guided high-prospect drug repositioning candidates for DMD via Swanson linking of target-focused latent knowledge from text-mined categorical metadata
by: J. Wes Ulm, et al.
Published: (2023-08-01)

Challenges for Drug Repurposing in the COVID-19 Pandemic Era
by: Janet Sultana, et al.
Published: (2020-11-01)

Cranial Manifestations of Neurofibromatosis Type 2: A Rare Case Demonstrating 15 Intracranial Lesions
by: Amit Kharat, et al.
Published: (2020-01-01)

Mixed schwannoma with meningioma of the trigeminal nerve
by: Jain Ayushi, et al.
Published: (2010-10-01)

A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease
by: Soo Youn Lee, et al.
Published: (2020-01-01)

Editorial: Drug Repurposing
by: Pan Pantziarka, et al.
Published: (2019-07-01)

Computational Drug Repositioning: Current Progress and Challenges
by: Younhee Ko
Published: (2020-07-01)

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing
by: Shuhei Suzuki, et al.
Published: (2020-08-01)

Development of Pigmentation-Regulating Agents by Drug Repositioning
by: Seo-Mi-Gon Jeong, et al.
Published: (2021-04-01)

Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression
by: Bessi Qorri, et al.
Published: (2022-03-01)

In silico drug repositioning based on the integration of chemical, genomic and pharmacological spaces
by: Hailin Chen, et al.
Published: (2021-02-01)

Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis
by: Suha Bachir, et al.
Published: (2021-01-01)

Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
by: Vanessa L. Merker, et al.
Published: (2022-02-01)

Leveraging Genomic and Bioinformatic Analysis to Enhance Drug Repositioning for Dermatomyositis
by: Lalu Muhammad Irham, et al.
Published: (2023-07-01)

A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions
by: Tamer N. Jarada, et al.
Published: (2020-07-01)